Limits...
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Following End-Stage Renal Disease

View Article: PubMed Central - PubMed

ABSTRACT

To investigate the risk of nonarteritic anterior ischemic optic neuropathy (NAION) following end-stage renal disease (ESRD).

A retrospective, nationwide, matched cohort study.

ESRD patients identified by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 585.

The study cohort included 93,804 ESRD patients registered with the Taiwan National Health Insurance Research Database between January 2000 and December 2009. An age- and sex-matched control group comprised 93,804 patients (case:control = 1:1) selected from the Taiwan Longitudinal Health Insurance Database 2000. Information for each patient was collected from the index date until December 2011. The incidence and risk of NAION were compared between the ESRD and control groups. The adjusted hazard ratio (HR) for NAION after adjustment for potential confounders was obtained by a Cox proportional hazard regression analysis. A Kaplan–Meier analysis was used to calculate the cumulative incidence rate of NAION.

The incidence of NAION following ESRD.

In total, 133 ESRD patients (0.14%) and 51 controls (0.05%) had NAION (P < 0.001) during the follow-up period, leading to a significantly elevated risk of NAION in the ESRD patients compared with the controls (incidence rate ratio = 3.14, 95% confidence interval [CI] = 2.11–4.67). After adjustment for potential confounders including diabetes mellitus, hypertension, hypotension, hyperlipidemia, and 2-way interaction terms between any 2 factors, ESRD patients were 3.12 times more likely to develop NAION than non-ESRD patients in the full cohort (adjusted HR = 3.12, 95% CI = 2.10–4.64). Additionally, patients with hypertension and hyperlipidemia showed higher incidence rates of NAION in the ESRD group compared with the controls: 2.31 (95% CI = 1.40–3.82) for hypertension and 2.72 (95% CI = 1.14–6.50) for hyperlipidemia.

ESRD increased the risk of NAION, which is an interdisciplinary emergency. Close collaboration between nephrologists and ophthalmologists is important in NAION management following ESRD to prevent fellow eye involvement.

No MeSH data available.


Related in: MedlinePlus

A Kaplan–Meier curve of the cumulative incidence of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with end-stage renal disease (ESRD) and the controls during the follow-up period.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998400&req=5

Figure 1: A Kaplan–Meier curve of the cumulative incidence of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with end-stage renal disease (ESRD) and the controls during the follow-up period.

Mentions: Kaplan–Meier survival analyses revealed higher NAION cumulative incidence rates in ESRD patients than in control patients, and the log-rank test was also significant (P < 0.001; Figure 1).


Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Following End-Stage Renal Disease
A Kaplan–Meier curve of the cumulative incidence of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with end-stage renal disease (ESRD) and the controls during the follow-up period.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998400&req=5

Figure 1: A Kaplan–Meier curve of the cumulative incidence of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with end-stage renal disease (ESRD) and the controls during the follow-up period.
Mentions: Kaplan–Meier survival analyses revealed higher NAION cumulative incidence rates in ESRD patients than in control patients, and the log-rank test was also significant (P < 0.001; Figure 1).

View Article: PubMed Central - PubMed

ABSTRACT

To investigate the risk of nonarteritic anterior ischemic optic neuropathy (NAION) following end-stage renal disease (ESRD).

A retrospective, nationwide, matched cohort study.

ESRD patients identified by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 585.

The study cohort included 93,804 ESRD patients registered with the Taiwan National Health Insurance Research Database between January 2000 and December 2009. An age- and sex-matched control group comprised 93,804 patients (case:control&#8202;=&#8202;1:1) selected from the Taiwan Longitudinal Health Insurance Database 2000. Information for each patient was collected from the index date until December 2011. The incidence and risk of NAION were compared between the ESRD and control groups. The adjusted hazard ratio (HR) for NAION after adjustment for potential confounders was obtained by a Cox proportional hazard regression analysis. A Kaplan&ndash;Meier analysis was used to calculate the cumulative incidence rate of NAION.

The incidence of NAION following ESRD.

In total, 133 ESRD patients (0.14%) and 51 controls (0.05%) had NAION (P&#8202;&lt;&#8202;0.001) during the follow-up period, leading to a significantly elevated risk of NAION in the ESRD patients compared with the controls (incidence rate ratio&#8202;=&#8202;3.14, 95% confidence interval [CI]&#8202;=&#8202;2.11&ndash;4.67). After adjustment for potential confounders including diabetes mellitus, hypertension, hypotension, hyperlipidemia, and 2-way interaction terms between any 2 factors, ESRD patients were 3.12 times more likely to develop NAION than non-ESRD patients in the full cohort (adjusted HR&#8202;=&#8202;3.12, 95% CI&#8202;=&#8202;2.10&ndash;4.64). Additionally, patients with hypertension and hyperlipidemia showed higher incidence rates of NAION in the ESRD group compared with the controls: 2.31 (95% CI&#8202;=&#8202;1.40&ndash;3.82) for hypertension and 2.72 (95% CI&#8202;=&#8202;1.14&ndash;6.50) for hyperlipidemia.

ESRD increased the risk of NAION, which is an interdisciplinary emergency. Close collaboration between nephrologists and ophthalmologists is important in NAION management following ESRD to prevent fellow eye involvement.

No MeSH data available.


Related in: MedlinePlus